.png){kind=icon}
.png){kind=icon}
Return
Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-report
.png){kind=icon}
PRE
AI
M
S
T
K
E
S
DOI：10.1016/j.jbspin.2024.105754.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Introduction: Denosumab (Dmab) is widely used for the treatment of post-menopausal osteoporosis. Its discontinuation is sometimes accompanied by multiple vertebral fractures. Romosozumab (Rmab) has not been tested for its ability to prevent the rebound phenomenon. Case presentation: We present the case of a 68-year-old female patient with post-menopausal osteoporosis under treatment with Rmab who presented with multiple vertebral fractures after denosumab discontinuation. The addition of Rmab did not prevent new-onset rebound-associated vertebral fractures. The patient discontinued Rmab and Dmab was re-initiated. After six months, no new vertebral fractures occurred, bone mineral density increased and bone turnover markers remained suppressed. Discussion: Our clinical case illustrates the ineffectiveness of Rmab to prevent the multiple vertebral fracture cascade attributable to discontinuation of Dmab. We believe that treatment with Rmab might not be enough to prevent this phenomenon. Treatment with Dmab or possibly combination treatment with Dmab and Rmab could be another treatment option. (c) 2024 Soci oto Fran oaise de Rhumatologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Keywords:
Rebound
Denosumab
Vertebral fractures
Romosozumab
Journal
IF:
4.3
Papers:
4.2K
Citations:
4.8K
Organization
No organization information available
Cited Papers